The role of Toll-like receptors in retinal ischemic diseases.
Toll-like receptors (TLRs) are commonly referred to a series of evolutionary conserved receptors which recognize and respond to various microbes and endogenous ligands. Growing evidence has demonstrated that the expression of TLRs in the retina is regulated during retinal ischemic diseases, including ischemia-reperfusion injury, glaucoma, diabetic retinopathy (DR) and retinopathy of prematurity (ROP). TLRs can be expressed in multiple cells in the retina, such as glial cells, retinal pigment epithelium (RPE), as well as photoreceptor cells and endothelium cells. Activation of TLRs in retina could initiate a complex signal transduction cascade, induce the production of inflammatory cytokines and regulate the level of co-stimulatory molecules, which play prominent roles in the pathogenesis of retinal ischemic diseases. In this review, we summarized current studies about the relationship between TLRs and ischemic retinopathy. A greater understanding of the effect of TLRs on ischemic injuries may contribute to the development of specific TLR targeted therapeutic strategies in these conditions.
Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China.
Wen-Qin
WQ
Xu
Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China.
Yu-Sheng
YS
Wang
Toll-like receptors; retinal ischemic diseases; retinal regeneration; retinopathy
Nat Immunol. 2008 Apr;9(4):361-8
18297073
Invest Ophthalmol Vis Sci. 2014 Feb 10;55(2):824-31
24425851
Exp Neurol. 2014 Aug;258:5-16
25017883
Am Heart J. 2004 Dec;148(6):1034-40
15632890
Invest Ophthalmol Vis Sci. 2011 Dec 28;52(13):9710-20
22110078
Mol Neurobiol. 1987 Spring-Summer;1(1-2):9-46
3077059
Nat Immunol. 2010 May;11(5):373-84
20404851
PLoS One. 2014 Jan 31;9(1):e87574
24498140
J Neuroinflammation. 2014 Apr 23;11:81
24755298
J Pathol. 2006 Nov;210(3):315-24
16981238
Am J Surg. 2007 Jun;193(6):730-5
17512285
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5697-707
20538986
Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5824-35
21666244
Exp Eye Res. 2013 May;110:125-35
23375594
Invest Ophthalmol Vis Sci. 2011 Sep 09;52(10):7187-94
21828158
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11181-6
25024200
Mediators Inflamm. 2014;2014:858763
25214718
J Neurosci. 2000 May 15;20(10):3552-62
10804196
Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5807-16
23908181
Diabetes Care. 2004 Jan;27(1):179-83
14693986
Diabetes. 2014 Nov;63(11):3926-37
24947354
Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11
7507904
Am J Pathol. 2012 Jan;180(1):209-20
22085974
Nat Cell Biol. 2007 Sep;9(9):1081-8
17704767
Shock. 2009 Jul;32(1):4-16
19008778
Shock. 2010 Dec;34(6):548-57
20458266
Acta Ophthalmol. 2014 Dec;92(8):e621-9
24930695
Prog Retin Eye Res. 2015 Mar;45:30-57
25476242
PLoS One. 2012;7(1):e29830
22253793
Invest Ophthalmol Vis Sci. 2014 Nov 18;56(1):232-42
25406276
Exp Eye Res. 2015 Sep;138:114-23
26091789
Nature. 1980 Oct 30;287(5785):795-801
6776413
J Neuroimmunol. 2004 Aug;153(1-2):7-15
15265658
Am J Pathol. 2014 Jun;184(6):1900-10
24726642
Physiol Rev. 2005 Jul;85(3):845-81
15987797
Br J Ophthalmol. 2013 Dec;97(12):1598-603
24133029
Science. 2003 Jun 6;300(5625):1524-5
12791976
Eur J Neurosci. 2009 Jul;30(2):175-85
19614983
J Neuroinflammation. 2014 Mar 28;11:62
24678770
Invest Ophthalmol Vis Sci. 2014 Jun 03;55(6):3957-70
24894399
Invest Ophthalmol Vis Sci. 2013 Dec 17;54(13):8125-39
24204040
J Neurosci. 2008 Dec 17;28(51):13978-84
19091986
Br J Ophthalmol. 2013 Oct;97(10):1343-50
23913246
Curr Eye Res. 2011 Nov;36(11):1037-46
21999229
Nat Immunol. 2013 Jan;14(1):41-51
23179077
Oncogene. 2008 Jan 7;27(2):168-80
18176598
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):459-64
19661221
Glia. 2010 Jan 1;58(1):43-54
19544395
Prog Retin Eye Res. 2006 Jul;25(4):397-424
16839797
Neurol Sci. 2013 Aug;34(8):1339-46
23207548
Mol Vis. 2014 May 27;20:704-13
24883015
Br J Ophthalmol. 2006 Jan;90(1):103-8
16361678
Ophthalmic Res. 2007;39(3):155-63
17534115
J Neuroimmunol. 2011 Jan;230(1-2):183-7
20801528
J Clin Invest. 2006 Jul;116(7):1793-801
16823477
Mol Vis. 2011;17:1829-38
21850157
Lancet. 2010 Jul 10;376(9735):124-36
20580421
Lancet. 1997 Jul 19;350(9072):197-204
9250197
J Perinatol. 2008 Jan;28(1):61-6
18046338
J Neuroinflammation. 2012 Feb 24;9:39
22361049
J Infect Dis. 2010 Jan 15;201(2):255-63
19995266
Infect Immun. 2012 Jun;80(6):2076-88
22431652
Prog Retin Eye Res. 2013 Sep;36:260-80
23830845
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4769-76
19443727
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):330-8
23241411
Front Immunol. 2014 Sep 25;5:461
25309543
Invest Ophthalmol Vis Sci. 2012 Jun 28;53(7):4220-33
22570341
J Immunol. 2008 Mar 15;180(6):3789-96
18322185
J Exp Med. 2004 Jan 5;199(1):81-90
14699082
J Neuroinflammation. 2014 May 15;11:87
24886524
Nature. 2008 Apr 3;452(7187):591-7
18368052
Mol Vis. 2010 Sep 30;16:1907-12
21031135
Trends Immunol. 2004 Jan;25(1):4-7
14698276
Clin Exp Immunol. 2007 Jan;147(1):71-80
17177965
FASEB J. 2007 Dec;21(14):3904-16
17628015
Nat Commun. 2014 Jun 10;5:4047
24915161
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5071-82
20484586
Arch Ophthalmol. 2011 Dec;129(12):1555-63
22159674
Ophthalmology. 2015 Jan;122(1):200-10
25444347
PLoS One. 2013 Jul 11;8(7):e68871
23874797
J Immunol. 2011 Jun 15;186(12):7089-97
21602496
J Neurochem. 2012 Feb;120(4):586-97
22118627
Early Hum Dev. 2009 May;85(5):325-9
19217727
Immunol Res. 2010 Jul;47(1-3):153-61
20082152
Invest Ophthalmol Vis Sci. 2014 Aug 05;55(9):5466-75
25097240
Hum Immunol. 2009 Feb;70(2):121-4
19135114
J Neurosci Res. 2003 Apr 1;72(1):125-31
12645086
Immunity. 2002 Sep;17(3):251-63
12354379
J Cell Biol. 2008 Nov 3;183(3):393-400
18981228
Br J Ophthalmol. 2015 Jan;99(1):125-32
25355806